

Company Announcement

17 May 2010

## Bavarian Nordic Begins Delivery of IMVAMUNE® to the U.S. Strategic National Stockpile

Kvistgård, Denmark, May 17, 2010 - Bavarian Nordic A/S (OMX: BAVA) announced today that it has initiated delivery of its smallpox vaccine IMVAMUNE® to the U.S. Strategic National Stockpile. The delivery is part of Bavarian Nordic's contract with BARDA, to deliver 20 million doses of IMVAMUNE®.

The above does not impact the company's financial guidance for the year 2010.

Asger Aamund Chairman of the Board

## Contact

Anders Hedegaard, President & CEO. Phone +45 23 20 30 64

## About Bavarian Nordic

Bavarian Nordic A/S is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's pipeline is focused in the three areas; cancer, biodefence and infectious diseases, and includes seven development programmes. Two programmes are under preparation for Phase III:  $PROSTVAC^{TM}$ , a therapeutic vaccine for advanced prostate cancer is being developed under a collaboration agreement with the National Cancer Institute, and IMVAMUNE®, a third-generation smallpox vaccine is being developed under a contract with the US government.

Bavarian Nordic is listed on NASDAQ OMX Copenhagen under the symbol BAVA.

For more information please visit  $\underline{www.bavarian-nordic.com}$ 

## Forward-looking statements

This announcement includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Page 1 of 1 Company Announcement no. 25 / 2010